Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and sorafenib

cyc 202 has been researched along with sorafenib in 11 studies

Compound Research Comparison

Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010)
(cyc 202)		Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010) (sorafenib)
97973936,5207305,251

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)sorafenib (IC50)
Aurora kinase AHomo sapiens (human)3.8
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)3.6
Bile salt export pumpHomo sapiens (human)8.6667
Tyrosine-protein kinase ABL1Homo sapiens (human)0.1
Tyrosine-protein kinase ABL1Mus musculus (house mouse)0.2259
Epidermal growth factor receptorHomo sapiens (human)0.2145
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.1333
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.131
Platelet-derived growth factor receptor betaMus musculus (house mouse)0.1235
Insulin receptorHomo sapiens (human)5.3
Tyrosine-protein kinase LckHomo sapiens (human)0.06
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0385
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.026
Hepatocyte growth factor receptorHomo sapiens (human)5.75
Tyrosine-protein kinase HCKHomo sapiens (human)0.53
Platelet-derived growth factor receptor betaHomo sapiens (human)0.1164
Serine/threonine-protein kinase A-RafHomo sapiens (human)0.0087
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.1937
Fibroblast growth factor receptor 1Homo sapiens (human)0.2827
AromataseHomo sapiens (human)0.1269
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.39
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.3699
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.427
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.06
Cyclin-CHomo sapiens (human)0.0663
Mitogen-activated protein kinase 3 Homo sapiens (human)0.0181
Serine/threonine-protein kinase B-raf Mus musculus (house mouse)0.13
Mitogen-activated protein kinase 1Homo sapiens (human)0.1095
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)0.0011
Bifunctional epoxide hydrolase 2Homo sapiens (human)0.012
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0191
Vascular endothelial growth factor receptor 3Mus musculus (house mouse)0.1269
Vascular endothelial growth factor receptor 2Mus musculus (house mouse)0.1129
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.1
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0348
Casein kinase I isoform alphaHomo sapiens (human)0.25
Cyclin-dependent kinase 8Homo sapiens (human)1.1294
Glycogen synthase kinase-3 betaHomo sapiens (human)5.77
Ephrin type-B receptor 4Homo sapiens (human)0.5442
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)6.1
Cyclin-dependent kinase 6Homo sapiens (human)0.13
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)3.3
Angiopoietin-1 receptorHomo sapiens (human)0.0032
Tyrosine-protein kinase MerHomo sapiens (human)1.37
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)1.5
Mitogen-activated protein kinase 14Homo sapiens (human)0.6228
Discoidin domain-containing receptor 2Homo sapiens (human)0.0215
Serine/threonine-protein kinase TNNI3KHomo sapiens (human)0.175
Vascular endothelial growth factor receptor 2Danio rerio (zebrafish)2.6
Homeodomain-interacting protein kinase 1Homo sapiens (human)0.1
Homeodomain-interacting protein kinase 4Homo sapiens (human)0.0515
Cyclin-dependent kinase 19Homo sapiens (human)0.206
Homeodomain-interacting protein kinase 2Homo sapiens (human)0.1
Homeodomain-interacting protein kinase 3Homo sapiens (human)0.1
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)0.262
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)3.1

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's5 (45.45)24.3611
2020's2 (18.18)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Russu, WA; Shallal, HM1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Cheng, W; Kan, Q; Li, Y; Tian, X; Wang, S; Wei, H; Yang, Z1
Bharate, SB; Raghuvanshi, R1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A1
Fesik, SW; Huang, X; Li, L; Lin, X; Morgan-Lappe, S; Shen, Y; Vernetti, LA; Zakula, DM1
Akli, S; Duong, MT; Hunt, KK; Keyomarsi, K; Liu, W; Lu, Y; Mills, GB; Wei, C; Wingate, HF; Yi, M1

Reviews

2 review(s) available for cyc 202 and sorafenib

ArticleYear
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
    European journal of medicinal chemistry, 2019, Feb-15, Volume: 164

    Topics: Animals; Crystallography, X-Ray; Cyclin-Dependent Kinases; Humans; Molecular Structure; Protein Binding; Protein Kinase Inhibitors

2019
Kinase Inhibitors as Underexplored Antiviral Agents.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses

2022

Other Studies

9 other study(ies) available for cyc 202 and sorafenib

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
The selectivity of protein kinase inhibitors: a further update.
    The Biochemical journal, 2007, Dec-15, Volume: 408, Issue:3

    Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera

2007
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022
'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Oncogene, 2007, Jun-07, Volume: 26, Issue:27

    Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; bcl-X Protein; Benzenesulfonates; Biphenyl Compounds; Blotting, Western; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; RNA Interference; RNA, Small Interfering; Roscovitine; Sorafenib; Sulfonamides; Transmembrane Activator and CAML Interactor Protein; Zinc Fingers

2007
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
    PLoS genetics, 2012, Volume: 8, Issue:3

    Topics: Acinar Cells; Animals; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin E; Cyclin-Dependent Kinase 2; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Isoforms; Proto-Oncogene Proteins B-raf; Purines; Pyridines; Retrospective Studies; Roscovitine; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases

2012